⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

Globus Medical stock soars to all-time high of $85.89

Published 11/29/2024, 10:06 AM
GMED
-

Globus Medical Inc. (NYSE:GMED), now valued at $11.62 billion, has reached an impressive milestone, with its stock price soaring to an all-time high of $85.89. This peak reflects a significant surge in investor confidence, as evidenced by the company's remarkable 1-year return of 90.25%. According to InvestingPro analysis, while the stock's RSI suggests overbought territory, the company maintains a GREAT financial health score. The ascent to this record price level underscores the medical device company's robust performance, with impressive revenue growth of 102.1% and a strong current ratio of 2.51. Investors are closely monitoring Globus Medical (TASE:PMCN)'s trajectory, as it continues to innovate in the musculoskeletal solutions space, potentially setting the stage for further gains. For deeper insights into GMED's valuation and growth prospects, InvestingPro offers 17 additional investment tips and a comprehensive Pro Research Report.

In other recent news, Globus Medical has reported significant growth in its Q3 2024 earnings call. The company's sales saw a considerable increase, reaching $626 million, reflecting a 63% growth year-over-year. The Non-GAAP EPS also reached a record high of $0.83, up by 45%. This impressive growth was primarily driven by strong U.S. spine sales, international expansion, and the ongoing integration of the NuVasive (NASDAQ:NUVA) merger.

The company also revised its 2024 net sales guidance to $2.49 billion to $2.5 billion, with Non-GAAP EPS guidance adjusted to $2.90 to $3 per share. Globus Medical is focusing on integration and cost synergies, expecting to save $170 million over three years.

Looking ahead, the company is optimistic about its prospects in 2025, planning to leverage synergy with robotics, particularly in orthopedics. Despite a decrease in gross profit margin to 53% due to amortization from the merger, and FDA scrutiny regarding internal complaint handling processes, Globus Medical is confident in its trajectory, anticipating stronger growth through increased cross-selling and operational improvements in 2025. These are the recent developments for Globus Medical.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.